MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/20406207261475918

Медицинская библиотека · Therapeutic advances in hematology · 2026

Quality improvement project - Implementation of subcutaneous immunoglobulin in patients with haematological disorders and secondary immunodeficiency.

Chaudry Amira, Culpin Rebecca, Elshazly Shereen

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Immunoglobulins (Ig) play a crucial role in the immune system's ability to fight infections. In incidences when their production and function is disrupted, such as in secondary immunodeficiency (SID), patients often face increased frequency and severity of infection, particularly respiratory tract infections. Ig replacement therapy administered intravenously (IVIG) or subcutaneously (SCIG) is recommended for treatment of SID, including SID caused by haematological malignancies. Subregional Ig assessment panels (SRIAPs) and prefilled syringes (PFS) for SCIG may positively impact services across the Trust and wider National Health Service (NHS) and increase patient satisfaction and treatment outcomes.

OBJECTIVES

Investigate the improvement in service delivery and patient satisfaction following the switch from IVIG to SCIG PFS manual push in patients with SID following an East of England Immunoglobulin Assessment Panel (EOE IAP) review.

DESIGN

Following establishment of the EOE IAP, three cohorts of patients with haematological disorders and SID, currently receiving IVIG across the Mid and South Essex NHS Foundation trust, were reviewed before switching to SCIG PFS. This manuscript reports the findings from one of the three cohorts, based at Broomfield Hospital.

METHODS

Following clinical screening, patients were reviewed by the local SRIAP to assess Ig use and suitability for transfer from IVIG to SCIG PFS. Patient outcomes and satisfaction, financial measurements, and prescribing information after transition were recorded.

RESULTS

SRIAP review of Ig prescribing for ten patients resulted in six transitioning from IVIG to SCIG PFS. Patients reported improved infection rates and satisfaction with home-based SCIG PFS treatment. Service outcomes reported savings in prescribing, pharmacy, and nursing time, as well as an increase in therapy chair capacity.

CONCLUSION

SRIAP reviews and switching to SCIG PFS can improve patient satisfaction and outcomes, help clinically vulnerable patients shield via home-based treatment, improve service efficacy and lower total treatment costs, whilst promoting Ig stewardship.

Для цитирования: Chaudry Amira, Culpin Rebecca, Elshazly Shereen. Quality improvement project - Implementation of subcutaneous immunoglobulin in patients with haematological disorders and secondary immunodeficiency.. Therapeutic advances in hematology. 2026. DOI: 10.1177/20406207261475918.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.